Document is current
Any future updates will be listed below
-
Authors
Segura, Àlex-González
Prohens, Llucia
Mezquida, Gisela
Amoretti, Silvia https://orcid.org/0000-0001-6017-2734
Bioque, Miquel
Ribeiro, María
Gurriarán-Bas, Xaquin
Rementería, Lide
Berge, Daniel
Rodriguez-Jimenez, Roberto
Roldán, Alexandra
Pomarol-Clotet, Edith
Ibáñez, Angela
Usall, Judith
García-Portilla, Maria Paz https://orcid.org/0000-0003-3643-1622
Cuesta, Manuel J.
Parellada, Mara
González-Pinto, Ana
Berrocoso, Esther https://orcid.org/0000-0003-0208-7472
Bernardo, Miquel https://orcid.org/0000-0001-8748-6717
Mas, Sergi https://orcid.org/0000-0003-3336-6298
,
González-Díaz, Jairo M.
Arbelo, Néstor
González-Peñas, Javier
Pina-Camacho, Laura
Diestre, Alba
Selma, Judit
Zorrilla, Iñaki
López, Purificación
Trabsa, Amira
Monserrat, Clara
Sanchez-Pastor, Luis
Nuñez-Doyle, Aggie
Fatjó-Vilas, Mar
Sarró, Salvador
Butjosa, Anna
Pardo, Marta
López-Ilundain, Jose M.
Sánchez Torres, Ana M.
Saiz-Ruiz, Jerónimo
Ochoa-Mangado, Enriqueta
RIevero, Olga
De-la-Cámara, Concepción
Echevarría, Rafael Segarra
González-Blanco, Leticia
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI14/00612)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (2017SGR1562, 2017SGR1355)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
- License Information
-
More Information
Article History
Received: 5 May 2022
Accepted: 4 July 2022
First Online: 22 July 2022
Competing interests
: A.I. has received research support from or served as speaker or advisor for Janssen-Cilag, Lundbeck and Otsuka. A.G.-P. has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Exeltis, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), and the Basque Government. J.S.-R. has been as speaker for and on the advisory boards of Adamed, Lundbeck, Servier, Medtronic, Casen Recordati, Neurofarmagen, Otsuka, Indivior, Lilly, Schwabe, Janssen and Pfizer, outside the submitted work. M.B. has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini and Rovi. T.M.B. has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of has received honoraria from talks and/or consultancy of Adamed, Angelini, Ferrer, Janssen-Cilag, Lundbeck, Neuraxpharm, Otsuka, Pfizer and Sanofi, and grants from Spanish Ministry of Health, Instituto de Salud Carlos III. M.G.F. has been on the speakers/advisory board of Janssen-Cilag. P.A.S. has been a consultant to and/or has received honoraria or grants from Adamed, CIBERSAM, European Comission, Government of the Principality of Asturias, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas and Servier. R.R.-J. has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; S2017/BMD-3740), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, Angelini. The rest of the authors reported no biomedical financial interests or potential conflicts of interest.
